GRI Bio (GRI) Competitors $1.81 -0.12 (-6.22%) As of 09/19/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRI vs. PRPH, THAR, LSB, BLRX, EDSA, MTVA, NRSN, AIMD, CLRB, and COCPShould you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include ProPhase Labs (PRPH), Tharimmune (THAR), LakeShore Biopharma (LSB), BioLineRx (BLRX), Edesa Biotech (EDSA), MetaVia (MTVA), NeuroSense Therapeutics (NRSN), Ainos (AIMD), Cellectar Biosciences (CLRB), and Cocrystal Pharma (COCP). These companies are all part of the "pharmaceutical products" industry. GRI Bio vs. Its Competitors ProPhase Labs Tharimmune LakeShore Biopharma BioLineRx Edesa Biotech MetaVia NeuroSense Therapeutics Ainos Cellectar Biosciences Cocrystal Pharma GRI Bio (NASDAQ:GRI) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations. Do analysts recommend GRI or PRPH? GRI Bio presently has a consensus price target of $22.00, indicating a potential upside of 1,115.47%. Given GRI Bio's stronger consensus rating and higher possible upside, research analysts clearly believe GRI Bio is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, GRI or PRPH? GRI Bio has higher earnings, but lower revenue than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGRI BioN/AN/A-$8.21M-$11.56-0.16ProPhase Labs$6.77M2.38-$53.36M-$1.26-0.31 Does the media favor GRI or PRPH? In the previous week, ProPhase Labs had 1 more articles in the media than GRI Bio. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for GRI Bio. GRI Bio's average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score. Company Overall Sentiment GRI Bio Neutral ProPhase Labs Neutral Is GRI or PRPH more profitable? ProPhase Labs' return on equity of -262.42% beat GRI Bio's return on equity.Company Net Margins Return on Equity Return on Assets GRI BioN/A -327.62% -191.40% ProPhase Labs N/A -262.42%-76.48% Which has more risk and volatility, GRI or PRPH? GRI Bio has a beta of -1.59, suggesting that its share price is 259% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.78, suggesting that its share price is 178% less volatile than the S&P 500. Do insiders and institutionals believe in GRI or PRPH? 34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are owned by institutional investors. 0.9% of GRI Bio shares are owned by company insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryProPhase Labs beats GRI Bio on 7 of the 13 factors compared between the two stocks. Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRI vs. The Competition Export to ExcelMetricGRI BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.55M$3.15B$5.79B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio-0.1620.9180.4326.78Price / SalesN/A448.41534.22123.54Price / CashN/A46.6037.9961.55Price / Book0.249.6615.776.40Net Income-$8.21M-$53.22M$3.30B$271.80M7 Day PerformanceN/A3.11%5.37%3.48%1 Month Performance24.83%7.56%8.10%9.89%1 Year Performance-75.85%11.15%81.36%28.43% GRI Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRIGRI Bio2.3895 of 5 stars$1.81-6.2%$22.00+1,115.5%-76.9%$4.55MN/A-0.161Gap UpPRPHProPhase Labs0.5185 of 5 stars$0.43-0.8%N/A-84.6%$18.01M$6.77M-0.34130THARTharimmune1.8981 of 5 stars$2.94-6.4%$17.00+478.2%+20.4%$17.87MN/A-0.482Gap DownLSBLakeShore Biopharma0.701 of 5 stars$0.81-3.1%N/A-91.6%$17.25M$85.67M0.00773BLRXBioLineRx2.616 of 5 stars$3.75-7.2%$26.00+593.3%-85.7%$17.22M$28.94M-0.4340EDSAEdesa Biotech1.1993 of 5 stars$2.47+2.7%$5.00+102.8%-43.2%$16.89MN/A-1.8720Gap UpMTVAMetaVia1.7745 of 5 stars$1.50+115.5%$7.50+400.0%N/A$16.84MN/A0.008News CoverageHigh Trading VolumeNRSNNeuroSense Therapeutics2.188 of 5 stars$1.16-4.9%$14.00+1,106.9%-9.6%$16.67MN/A-2.1510Positive NewsAIMDAinos0.9534 of 5 stars$3.39-4.8%N/A+52.5%$16.58M$110.87K-0.6840News CoverageCLRBCellectar Biosciences2.9914 of 5 stars$5.15+1.4%$375.00+7,181.6%-91.8%$16.22MN/A-0.2610Short Interest ↓Gap UpCOCPCocrystal Pharma2.1285 of 5 stars$1.43-9.5%$6.00+319.6%-24.4%$16.21MN/A-1.1510News CoverageShort Interest ↑Gap Down Related Companies and Tools Related Companies PRPH Alternatives THAR Alternatives LSB Alternatives BLRX Alternatives EDSA Alternatives MTVA Alternatives NRSN Alternatives AIMD Alternatives CLRB Alternatives COCP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRI) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRI Stock Alerts